Hereditary papillary renal carcinoma type I

被引:69
作者
Dharmawardana, PG [1 ]
Giubellino, A [1 ]
Bottaro, DP [1 ]
机构
[1] NCI, Ctr Canc Res, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
关键词
c-Met; HGF/SF; HPRC; missense mutations; renal carcinoma;
D O I
10.2174/1566524043359674
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor/scatter factor (HGF/SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF/SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF/SF and c-Met function in health and disease.
引用
收藏
页码:855 / 868
页数:14
相关论文
共 112 条
[1]   Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx [J].
Aebersold, DM ;
Landt, O ;
Berthou, S ;
Gruber, G ;
Beer, KT ;
Greiner, RH ;
Zimmer, Y .
ONCOGENE, 2003, 22 (52) :8519-8523
[2]   Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions [J].
Atabey, N ;
Gao, Y ;
Yao, ZJ ;
Breckenridge, D ;
Soon, L ;
Soriano, JV ;
Burke, TR ;
Bottaro, DP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) :14308-14314
[3]   Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth [J].
Bardelli, A ;
Longati, P ;
Gramaglia, D ;
Basilico, C ;
Tamagnone, L ;
Giordano, S ;
Ballinari, D ;
Michieli, P ;
Comoglio, PM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14379-14383
[4]   The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants [J].
Berthou, S ;
Aebersold, DM ;
Schmidt, LS ;
Stroka, D ;
Heigl, C ;
Streit, B ;
Stalder, D ;
Gruber, G ;
Liang, CX ;
Howlett, AR ;
Candinas, D ;
Greiner, RH ;
Lipson, KE ;
Zimmer, Y .
ONCOGENE, 2004, 23 (31) :5387-5393
[5]   Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase [J].
Birchmeier, C ;
Gherardi, E .
TRENDS IN CELL BIOLOGY, 1998, 8 (10) :404-410
[6]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[7]  
Birchmeier W, 1997, CIBA F SYMP, V212, P230
[8]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[9]   Structure sand function of hemidesmosomes: More than simple adhesion complexes [J].
Borradori, L ;
Sonnenberg, A .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (04) :411-418
[10]   Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity [J].
Chiara, F ;
Michieli, P ;
Pugliese, L ;
Comoglio, PM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (31) :29352-29358